Liquidia (NASDAQ:LQDA) Earns "Buy" Rating from Needham & Company LLC

Liquidia (NASDAQ:LQDA - Get Free Report)'s stock had its "buy" rating reissued by equities researchers at Needham & Company LLC in a research note issued to investors on Monday, Benzinga reports. They currently have a $28.00 target price on the stock. Needham & Company LLC's price objective would suggest a potential upside of 87.67% from the company's current price.

Several other analysts have also issued reports on LQDA. Wedbush reaffirmed an "underperform" rating and issued a $3.00 target price on shares of Liquidia in a research note on Thursday, December 21st. LADENBURG THALM/SH SH upped their target price on Liquidia from $15.00 to $30.00 and gave the stock a "buy" rating in a research note on Thursday, December 21st. HC Wainwright upped their target price on Liquidia from $16.00 to $32.00 and gave the stock a "buy" rating in a research note on Thursday, March 14th. Finally, Bank of America upped their target price on Liquidia from $13.00 to $15.00 and gave the stock a "buy" rating in a research note on Thursday, December 21st. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to data from MarketBeat.com, Liquidia has an average rating of "Moderate Buy" and a consensus target price of $21.00.

Liquidia Trading Up 1.2 %

Shares of NASDAQ LQDA traded up $0.17 during midday trading on Monday, hitting $14.92. 1,284,333 shares of the company's stock were exchanged, compared to its average volume of 992,528. Liquidia has a 12-month low of $5.71 and a 12-month high of $16.99. The company has a market cap of $1.13 billion, a price-to-earnings ratio of -12.43 and a beta of 0.14. The business's fifty day moving average price is $14.32 and its two-hundred day moving average price is $10.27.

Insider Activity

In other news, CEO Roger Jeffs sold 28,583 shares of the stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $15.82, for a total transaction of $452,183.06. Following the completion of the sale, the chief executive officer now owns 835,345 shares of the company's stock, valued at $13,215,157.90. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, CFO Michael Kaseta sold 12,166 shares of the company's stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $15.82, for a total transaction of $192,466.12. Following the completion of the transaction, the chief financial officer now owns 318,181 shares in the company, valued at $5,033,623.42. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Roger Jeffs sold 28,583 shares of the company's stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $15.82, for a total value of $452,183.06. Following the transaction, the chief executive officer now owns 835,345 shares of the company's stock, valued at approximately $13,215,157.90. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 54,605 shares of company stock valued at $862,904. 31.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Liquidia

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. raised its holdings in shares of Liquidia by 2.5% during the fourth quarter. Vanguard Group Inc. now owns 2,843,922 shares of the company's stock valued at $34,212,000 after acquiring an additional 69,524 shares in the last quarter. Wellington Management Group LLP bought a new position in shares of Liquidia during the fourth quarter valued at approximately $849,000. Price T Rowe Associates Inc. MD raised its holdings in Liquidia by 9.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 11,342 shares of the company's stock worth $137,000 after purchasing an additional 989 shares in the last quarter. Bluefin Capital Management LLC bought a new position in Liquidia in the fourth quarter worth $302,000. Finally, Barclays PLC raised its holdings in Liquidia by 1,105.2% in the fourth quarter. Barclays PLC now owns 103,021 shares of the company's stock worth $1,239,000 after purchasing an additional 94,473 shares in the last quarter. Institutional investors own 64.54% of the company's stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).